Access to acute anemia agent under study may be expanded

News
Article

Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis.

Access to acute anemia agent under study may be expanded Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis. The draft protocol lists the eligibility criteria for patients. The Cambridge, Mass., firm is awaiting word from the FDA to its draft protocol.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.